Compare Stocks

→ Strange new buyer driving up gold (From Stansberry Research) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADIL Adial Pharmaceuticals	$1.98 -8.8%	$1.61	$0.76 ▼ $14.00	$8.02M	1.48	5.29 million shs	268,209 shs
EYEG AB Corporate Bond ETF	$34.66 -0.2%	$1.90	$1.44 ▼ $8.18	$437.31M	0.81	935,975 shs	1 shs
IGXT IntelGenx Technologies	$0.17 +6.3%	$0.16	$0.09 ▼ $0.22	$29.69M	2.43	89,940 shs	73,325 shs
MYOS MYOS RENS Technology		$3.35	$0.74 ▼ $3.85	$16.70M	1.08	1.68 million shs	N/A
RGLS Regulus Therapeutics	$2.13 -4.1%	$2.12	$1.08 ▼ $3.79	$139.43M	1.57	2.54 million shs	182,889 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADIL Adial Pharmaceuticals	-6.47%	-27.18%	+31.52%	+64.39%	-71.05%
EYEG AB Corporate Bond ETF	-0.20%	-0.69%	-2.20%	-2.39%	+1,677.18%
IGXT IntelGenx Technologies	+6.25%	-5.74%	+3.53%	+6.25%	-15.00%
MYOS MYOS RENS Technology	0.00%	0.00%	-2.14%	-55.37%	+358.19%
RGLS Regulus Therapeutics	-5.13%	-20.14%	-6.92%	+81.97%	+79.03%

Strange new buyer driving up gold (Ad)

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

But there's a much better move you can make to get in front of these big moves today.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EYEG AB Corporate Bond ETF	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IGXT IntelGenx Technologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MYOS MYOS RENS Technology	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RGLS Regulus Therapeutics	2.322 of 5 stars	4.4	2.0	0.0	0.0	2.1	1.7	0.0

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A
EYEG AB Corporate Bond ETF	N/A	N/A	N/A	N/A
IGXT IntelGenx Technologies	N/A	N/A	N/A	N/A
MYOS MYOS RENS Technology	N/A	N/A	N/A	N/A
RGLS Regulus Therapeutics	2.80	Moderate Buy	$7.25	240.38% Upside

Current Analyst Ratings

Latest EYEG, RGLS, IGXT, MYOS, and ADIL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/25/2024	RGLS Regulus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
3/19/2024	RGLS Regulus Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $11.00
3/18/2024	RGLS Regulus Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
3/18/2024	RGLS Regulus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
3/18/2024	RGLS Regulus Therapeutics	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$6.00
3/13/2024	RGLS Regulus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$2.00 ➝ $3.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	$2.46 per share	N/A
EYEG AB Corporate Bond ETF	$10K	43,731.14	N/A	N/A	$1.26 per share	27.50
IGXT IntelGenx Technologies	$1.04M	28.55	N/A	N/A	($0.07) per share	-2.43
MYOS MYOS RENS Technology	$1.03M	0.00	N/A	N/A	$0.13 per share	0.00
RGLS Regulus Therapeutics	N/A	N/A	N/A	N/A	$1.05 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADIL Adial Pharmaceuticals	-$5.12M	-$5.72	N/A	N/A	N/A	N/A	-250.52%	-183.24%	5/10/2024 (Estimated)
EYEG AB Corporate Bond ETF	-$8.09M	-$1.68	N/A	N/A	N/A	N/A	-104.96%	-60.03%	N/A
IGXT IntelGenx Technologies	-$9.93M	-$0.06	N/A	∞	N/A	-955.44%	N/A	-128.18%	N/A
MYOS MYOS RENS Technology	-$4.26M	N/A	N/A	N/A	N/A	-277.82%	-166.68%	-104.95%	N/A
RGLS Regulus Therapeutics	-$30.04M	-$1.59	N/A	N/A	N/A	N/A	-109.21%	-80.55%	5/9/2024 (Estimated)

Latest EYEG, RGLS, IGXT, MYOS, and ADIL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/21/2024	Q4 2023	IGXT IntelGenx Technologies	N/A	-$0.02	-$0.02	-$0.03	N/A	$0.43 million
3/21/2024	Q4 2023	RGLS Regulus Therapeutics	-$0.40	-$0.40	N/A	-$0.40	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EYEG AB Corporate Bond ETF	N/A	N/A	N/A	N/A	N/A
IGXT IntelGenx Technologies	N/A	N/A	N/A	N/A	N/A
MYOS MYOS RENS Technology	N/A	N/A	N/A	N/A	N/A
RGLS Regulus Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest EYEG, RGLS, IGXT, MYOS, and ADIL Dividends

Announcement	Company	Period	Amount	Ex-Dividend Date	Record Date	Payable Date
3/28/2024	EYEG AB Corporate Bond ETF	Monthly	$0.1572	4/1/2024	4/2/2024	4/5/2024
2/29/2024	EYEG AB Corporate Bond ETF	Monthly	$0.1486	3/1/2024	3/4/2024	3/7/2024
1/31/2024	EYEG AB Corporate Bond ETF	Monthly	$0.1476	2/1/2024	2/2/2024	2/7/2024

(Data available from 1/1/2013 forward)

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADIL Adial Pharmaceuticals	N/A	4.90	4.90
EYEG AB Corporate Bond ETF	0.01	3.07	3.07
IGXT IntelGenx Technologies	N/A	0.41	0.40
MYOS MYOS RENS Technology	0.11	3.78	1.94
RGLS Regulus Therapeutics	N/A	3.31	3.31

Ownership

Institutional Ownership

Company	Institutional Ownership
ADIL Adial Pharmaceuticals	16.41%
EYEG AB Corporate Bond ETF	64.16%
IGXT IntelGenx Technologies	N/A
MYOS MYOS RENS Technology	4.97%
RGLS Regulus Therapeutics	92.38%

Insider Ownership

Company	Insider Ownership
ADIL Adial Pharmaceuticals	14.47%
EYEG AB Corporate Bond ETF	58.20%
IGXT IntelGenx Technologies	42.05%
MYOS MYOS RENS Technology	45.30%
RGLS Regulus Therapeutics	8.41%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ADIL Adial Pharmaceuticals	16	4.05 million	3.47 million	No Data
EYEG AB Corporate Bond ETF	14	12.62 million	5.28 million	Not Optionable
IGXT IntelGenx Technologies	4	174.66 million	101.21 million	Not Optionable
MYOS MYOS RENS Technology	15	12.19 million	N/A	Not Optionable
RGLS Regulus Therapeutics	30	65.46 million	59.96 million	Optionable

EYEG, RGLS, IGXT, MYOS, and ADIL Headlines

Source	Headline
	Regulus Therapeutics (NASDAQ:RGLS) Research Coverage Started at StockNews.com americanbankingnews.com - April 16 at 2:22 AM
	Regulus Therapeutics Inc. (NASDAQ:RGLS) Given Average Rating of "Moderate Buy" by Brokerages americanbankingnews.com - April 12 at 4:16 AM
	Regulus: It Is Finding Its Stride Despite Initial Setback In Targeting ADPKD seekingalpha.com - April 10 at 1:50 PM
	Buy Rating on Regulus’s RGLS8429 Backed by Positive Phase 1b Data and Unmet ADPKD Treatment Needs markets.businessinsider.com - March 28 at 2:29 PM
	Short Interest in Regulus Therapeutics Inc. (NASDAQ:RGLS) Expands By 9,244.3% marketbeat.com - March 27 at 10:53 AM
	Buy Rating Reaffirmed for Regulus Therapeutics Amid Promising Drug Development Milestones markets.businessinsider.com - March 26 at 3:28 AM
	Regulus Therapeutics (NASDAQ:RGLS) Given "Buy" Rating at HC Wainwright marketbeat.com - March 25 at 8:21 AM
	Regulus Therapeutics Inc (RGLS) Reports Year-End Earnings, Highlights Key Clinical Advancements finance.yahoo.com - March 23 at 10:30 AM
	Regulus Therapeutics Inc.: Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates finanznachrichten.de - March 22 at 7:21 AM
	RGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q4 2023 investorplace.com - March 21 at 11:00 PM
	Regulus: Q4 Earnings Snapshot timesunion.com - March 21 at 9:20 PM
	Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates finance.yahoo.com - March 21 at 4:20 PM
	Buy Rating Affirmed for Regulus Therapeutics on Promising RGLS8429 ADPKD Treatment Data markets.businessinsider.com - March 19 at 11:39 PM
	RGLS Mar 2024 7.500 put finance.yahoo.com - March 15 at 5:16 AM
	Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More finance.yahoo.com - March 14 at 2:15 PM
	$100 million fundraise for antisense firm working in nephrology thepharmaletter.com - March 13 at 7:40 PM
	Regulus’s Stock RGLS: Hold Rating Amidst Promising Yet Preliminary ADPKD Study Results and Financial Position markets.businessinsider.com - March 13 at 2:40 PM
	Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study zacks.com - March 13 at 1:11 PM
	Regulus Therapeutics Shares Soar on Funding, Study Data marketwatch.com - March 12 at 7:11 PM
	Regulus Surges 60% On Positive Outcome From Phase1b MAD Trial, Private Placement Of $100 Mln markets.businessinsider.com - March 12 at 2:10 PM
	Why Is Kidney Disease-Focused Regulus Therapeutics Stock Trading Higher On Tuesday? msn.com - March 12 at 2:10 PM
	Regulus cues up $100m placement on ADPKD drug data pharmaphorum.com - March 12 at 9:10 AM
	Consumer Prices Tick Higher in February as US Equity Futures Turn Mixed Pre-Bell msn.com - March 12 at 9:10 AM
	Regulus Announces $100 Mln Private Placement, Positive Data From Phase 1b MAD Trial Of RGLS8429 markets.businessinsider.com - March 12 at 9:10 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Adial Pharmaceuticals

NASDAQ:ADIL

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

AB Corporate Bond ETF

NASDAQ:EYEG

EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.

IntelGenx Technologies

OTCMKTS:IGXT

IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0053/2020, and INT0054/2020. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was incorporated in 1999 and is headquartered in Montreal, Canada.

MYOS RENS Technology

NASDAQ:MYOS

MedAvail Holdings, Inc. is a technology-enabled pharmacy company. It provides turnkey in-clinic pharmacy services through its proprietary robotic dispensing platform, the MedAvail MedCenter, and home delivery operations, to Medicare clinics. The firm helps patients to optimize drug adherence, resulting in better health outcomes. The company is headquartered in Mississauga, Canada.

Regulus Therapeutics

NASDAQ:RGLS

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial